| European Case Law Identifier: | ECLI:EP:BA:2012:T191108.20120131 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 31 January 2012 | ||||||||
| Case number: | T 1911/08 | ||||||||
| Application number: | 02721105.1 | ||||||||
| IPC class: | C07D 401/12 C07D 471/08 C07D 487/04 A61K 31/444 A61P 29/02 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | ||||||||
| Applicant name: | Merck Sharp & Dohme Corp. | ||||||||
| Opponent name: | JANSSEN PHARMACEUTICAL N.V. | ||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Main request and auxiliary requests 1 and 2: amendments (not allowable), disclaimer not accidental anticipation Auxiliary request 3: added matter (yes), no basis for "in humans Auxiliary request 4: remittal after amendment |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t081911eu1.html
Date retrieved: 17 May 2021